Drug intelligence / Profile preview

codavax-rsv

Development stage
Phase 1
Lead developer
Codagenix
Modality
Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration
Intranasal
01

Overview

CodaVax-RSV is a live-attenuated, intranasal vaccine candidate developed to prevent respiratory syncytial virus (RSV) infections in infants, young children, and adults. The vaccine is engineered using hundreds of strategic genomic modifications that slow viral replication, resulting in a genetically stable and attenuated RSV virus that expresses all RSV proteins as antigens. This design aims to elicit both mucosal and cellular immune responses, including neutralizing antibodies and CD8-positive T lymphocyte activation. CodaVax-RSV has demonstrated safety and immunogenicity in Phase 1 studies involving older adults and is currently being evaluated in pediatric populations. The primary indication for CodaVax-RSV is the prevention of RSV infection[1][2][4][5].

Brand names
codavax-rsv
Other names
live attenuated rsv vaccine codagenix
02

Targets

RSV F (Respiratory syncytial virus fusion protein)Respiratory syncytial virus-specific T-cell receptorCD8A (CD8 alpha/beta Coreceptor)

Beyond the preview

Go deeper on codavax-rsv.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on codavax-rsv.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call